Kiromic BioPharma Announces Changes in Management, Board of Directors
Kiromic BioPharma (NASDAQ: KRBP) announces management changes effective
- Appointment of Pietro Bersani as Interim CEO may bring fresh perspectives and leadership.
- Formation of a Disclosure Committee aims to improve transparency and compliance.
- Departure of Dr. Maurizio Chiriva raises concerns over leadership continuity.
Company Director Michael Nagel Appointed as New Chairman of the Board
Company Disclosure Committee Created
Effective
“I have been a member of the Kiromic Board of Directors since 2020, and I feel privileged to now lead this Company during this very pivotal year ahead. We have tremendous science, and a very important milestone to reach in the coming months,” stated Interim CEO Bersani. “The Kiromic leadership team is laser focused on realizing our goal of first in-human dosing and initiating clinical trials.”
The Company also announces the formation of a Disclosure Committee, comprised of the Company’s senior leaders, for the purpose of further strengthening the Company’s protocol, process and procedure related to disclosure requirements.
For more information, please see the Company’s recently filed Form 8-K: Inline XBRL Viewer (sec.gov).
About
From its heritage as a cancer vaccine development company, Kiromic is focused on discovering, developing, and commercializing novel immuno-oncology applications through its robust product pipeline. The pipeline development is leveraged through the Company’s proprietary target discovery engine called "DIAMOND." Kiromic's DIAMOND is where big data science meets target identification to dramatically compress the man-years and billions of drug development dollars required to develop a live drug. The Company maintains offices in
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the
- our goals and strategies;
- our future business development, financial condition and results of operations;
- expected changes in our revenue, costs or expenditures;
- growth of and competition trends in our industry;
- our expectations regarding demand for, and market acceptance of, our products;
- our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with;
- fluctuations in general economic and business conditions in the markets in which we operate; including those fluctuations caused by COVID-19; and
- relevant government policies and regulations relating to our industry.
In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading “Risk Factors” included in our Registration Statement on Form S-1, as amended (file no. 333-257427) , originally filed with the
The forward-looking statements made in this report relate only to events or information as of the date on which the statements are made in this report. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220203005382/en/
Global Head, Corporate Communications
ldyson@kiromic.com
973-986-5973
Source:
FAQ
What management changes occurred at Kiromic BioPharma on January 27, 2022?
What is the purpose of the new Disclosure Committee at Kiromic BioPharma?
How does the management change impact Kiromic BioPharma's strategy?